343 related articles for article (PubMed ID: 20460347)
41. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
Agnelli G; Sonaglia F
Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
[TBL] [Abstract][Full Text] [Related]
42. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
43. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
44. M-118, a novel, low-molecular-weight heparin for the potential treatment of cardiovascular disorders.
Shah H; Gurm HS
Curr Opin Investig Drugs; 2010 Sep; 11(9):1059-65. PubMed ID: 20730701
[TBL] [Abstract][Full Text] [Related]
45. Neutralisation of heparan sulphate and low molecular weight heparin by protamine.
Hubbard AR; Jennings CA
Thromb Haemost; 1985 Feb; 53(1):86-9. PubMed ID: 3158095
[TBL] [Abstract][Full Text] [Related]
46. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
[TBL] [Abstract][Full Text] [Related]
47. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
[TBL] [Abstract][Full Text] [Related]
48. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
49. Comparative effects of heparin and LMW heparin on hemostasis.
Hirsh J; Buchanan MR
Thromb Res Suppl; 1991; 14():11-7. PubMed ID: 1658966
[TBL] [Abstract][Full Text] [Related]
50. Porous Polymers as Universal Reversal Agents for Heparin Anticoagulants through an Inclusion-Sequestration Mechanism.
Lin F; Yu SB; Liu YY; Liu CZ; Lu S; Cao J; Qi QY; Zhou W; Li X; Liu Y; Tian J; Li ZT
Adv Mater; 2022 Jun; 34(23):e2200549. PubMed ID: 35499202
[TBL] [Abstract][Full Text] [Related]
51. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
52. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
53. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
54. Porous dynamic covalent polymers as promising reversal agents for heparin anticoagulants.
Zong Y; Xu YY; Wu Y; Liu Y; Li Q; Lin F; Yu SB; Wang H; Zhou W; Sun XW; Zhang DW; Li ZT
J Mater Chem B; 2022 May; 10(17):3268-3276. PubMed ID: 35357392
[TBL] [Abstract][Full Text] [Related]
55. Rational design of low-molecular weight heparins with improved in vivo activity.
Sundaram M; Qi Y; Shriver Z; Liu D; Zhao G; Venkataraman G; Langer R; Sasisekharan R
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):651-6. PubMed ID: 12525684
[TBL] [Abstract][Full Text] [Related]
56. Caltrop-like Small-Molecule Antidotes That Neutralize Unfractionated Heparin and Low-Molecular-Weight Heparin In Vivo.
Zong Y; Lei Z; Yu SB; Zhang LY; Wu Y; Feng K; Qi QY; Liu Y; Zhu Y; Guo P; Zhou W; Zhang DW; Li ZT
J Med Chem; 2024 Mar; 67(5):3860-3873. PubMed ID: 38407934
[TBL] [Abstract][Full Text] [Related]
57. In-vitro and ex-vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin.
Falkon L; Garí M; Gich I; Fontcuberta J
Thromb Res; 1998 Jan; 89(2):79-83. PubMed ID: 9630311
[No Abstract] [Full Text] [Related]
58. In vitro and in vivo characterization of a reversible synthetic heparin analog.
Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
[TBL] [Abstract][Full Text] [Related]
59. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
[TBL] [Abstract][Full Text] [Related]
60. Protamine reversal of low molecular weight heparin: clinically effective?
van Veen JJ; Maclean RM; Hampton KK; Laidlaw S; Kitchen S; Toth P; Makris M
Blood Coagul Fibrinolysis; 2011 Oct; 22(7):565-70. PubMed ID: 21959588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
